Additional Advances in Multiple Myeloma Research and Clinical Trials With Sarah Holstein, MD, PhD
Lyn Brook
Expert Analysis
Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holst...
Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be prese...
Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.  
Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares...
Come See Oncology Data Advisor and ConveyMED at ASH 2022!
Lyn Brook
Press
Are you attending the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans this weekend? Come visit Oncology Data Advisor and ConveyMED while you are there! We will be attending and conducting live interviews discussing the latest research, news, and updates from the conference. Visit us in the press area outside of rooms 256-257...
Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD
Keira Smith
Expert Analysis
In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).  
Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and empha...
CLL Society: A Valuable Resource for Patients and the Health Care Team, With Founder Brian Koffman, MD
Keira Smith
Expert Analysis
In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them.
Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.  
Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD
Keira Smith
Expert Analysis
In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.  
Additional Advances in Waldenstrom Macroglobulinemia Research and Clinical Trials With Morie Gertz, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Recent Updates in Waldenstrom Macroglobulinemia With Morie Gertz, MD In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the Mayo Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.
Additional Advances in Research: Waldenstrom Macroglobulinemia With Morie Gertz, MD
Keira Smith
Expert Analysis
In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the Mayo Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia (WM) session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.  
Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Staying Up To Date On Treatment of Myelofibrosis With John Mascarenhas, MD Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. 
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer With Anne Chiang, MD, PhD, and Henry Park, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usuall...
Understanding Clonal Hematopoiesis in Hematologic Malignancies With Rahul Banerjee, MD, Jeremy Meier, MD, and Samuel Rubinstein, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Understanding Clonal Hematopoiesis With Rahul Banerjee, Jeremy Meier, and Samuel Rubinstein Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies. 
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can foc...
An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor™ · An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.  
Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD
Lyn Brook
Expert Analysis
Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.  
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 2
Keira Smith
Expert Analysis
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.  Watch the first part of Ms. Shockney and Ms. Metsker's conversation here!
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 1
Keira Smith
Expert Analysis
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.